Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $191,436 | 94 | 99.8% |
| Food and Beverage | $287.54 | 4 | 0.1% |
| Travel and Lodging | $56.14 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $170,745 | 84 | $0 (2022) |
| Shire North American Group Inc | $20,889 | 12 | $0 (2019) |
| DePuy Synthes Sales Inc. | $133.87 | 2 | $0 (2019) |
| PFIZER INC. | $11.50 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $20,933 | 11 | Takeda Pharmaceuticals U.S.A., Inc. ($20,933) |
| 2021 | $99,622 | 48 | Takeda Pharmaceuticals U.S.A., Inc. ($99,622) |
| 2020 | $50,190 | 25 | Takeda Pharmaceuticals U.S.A., Inc. ($50,190) |
| 2019 | $20,927 | 14 | Shire North American Group Inc ($20,889) |
| 2018 | $107.95 | 1 | DePuy Synthes Sales Inc. ($107.95) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 04/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 04/05/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 04/05/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,569.99 | General |
| 04/05/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $523.33 | General |
| 03/15/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 03/03/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 03/03/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 01/11/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 01/11/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 01/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 12/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $4,186.66 | General |
| 12/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 12/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 12/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 12/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/22/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/06/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/06/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/04/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/19/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/11/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/11/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/05/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/05/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 356 | 375 | $367,119 | $40,140 |
| 2020 | 4 | 210 | 217 | $200,870 | $19,320 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 129 | 139 | $204,052 | $23,042 | 11.3% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 72 | 74 | $73,778 | $7,533 | 10.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 27 | 28 | $52,780 | $5,647 | 10.7% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 56 | 59 | $31,034 | $3,438 | 11.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 72 | 75 | $5,475 | $480.24 | 8.8% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 81 | 83 | $126,387 | $12,486 | 9.9% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 61 | 64 | $39,035 | $3,348 | 8.6% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 31 | 32 | $32,674 | $3,229 | 9.9% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 37 | 38 | $2,774 | $256.08 | 9.2% |
About Walter Simmons, M.D., MPH
Walter Simmons, M.D., MPH is a Emergency Medicine healthcare provider based in Avondale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023087293.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Walter Simmons, M.D., MPH has received a total of $191,780 in payments from pharmaceutical and medical device companies, with $20,933 received in 2022. These payments were reported across 99 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($191,436).
As a Medicare-enrolled provider, Simmons has provided services to 566 Medicare beneficiaries, totaling 592 services with total Medicare billing of $59,460. Data is available for 2 years (2020–2021), covering 9 distinct procedure/service records.
Practice Information
- Specialty Emergency Medicine
- Other Specialties Emergency Medicine
- Location Avondale, AZ
- Active Since 03/17/2006
- Last Updated 02/09/2015
- Taxonomy Code 207P00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023087293
Products in Payments
- EXPEDIUM (Device) $133.87
- ELIQUIS (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.